Table 1 Participant characteristics of the Amsterdam Dementia Cohort (ADC) and ADNI cohorts

MMSE, mean ± SD

28.2 ± 1.8

26.5 ± 2.4 ^a

20.5 ± 5 ^c

29.1 ± 1.2

27.7 ± 1.8 ^a

23.3 ± 2 ^c

Age, mean ± SD

59.6 ± 8.9

66.4 ± 8.2 ^a

66.2 ± 8.1 ^a

73.8 ± 5.9

72.4 ± 7.5 ^a

74.9 ± 8.1 ^b

Female, n (%)

306 (41.4%)

217 (36.7%) ^a

674 (52%) ^c

195 (52.6%)

255 (41%) ^a

95 (41.7%) ^c

APOE e4 carrier, n (%) NC

258 (36.3%)

287 (52.4%) ^a

791 (65.3%) ^c

103 (27.8%)

307 (49.4%) ^a

154 (67.5%) ^c

Innotest: T-tau (pg/ml), mean ± SD

296.4 ± 200.8

466.4 ± 303.6 ^a

716.6 ± 417.1 ^c

n.a.

n.a.

n.a.

Innotest: P-tau (pg/ml), mean ± SD

48.4 ± 22.7

66.8 ± 33.6 ^a

87.6 ± 39.5 ^c

n.a.

n.a.

n.a.

Innotest: Aβ42 (pg/ml), mean ± SD

1071.2 ± 246.9

859.1 ± 288.1 ^a

648.4 ± 166.6 ^c

n.a.

n.a.

n.a.

Innotest: Abnormal Aβ42 (< 813 pg/ml), n (%)

124 (16.8%)

326 (55.2%) ^a

1173 (90.5%) ^c

n.a.

n.a.

n.a.

Luminex T-tau (pg/ml), mean ± SD

n.a.

n.a.

n.a.

67.4 ± 32.8

90.4 ± 54.8 ^a

126.6 ± 61.4 ^c

Luminex P-tau (pg/ml), mean ± SD

n.a.

n.a.

n.a.

32.4 ± 18.8

39.2 ± 23.7 ^a

51.6 ± 30.7 ^c

Luminex Aβ42 (pg/ml), mean ± SD

n.a.

n.a.

n.a.

201.7 ± 51.9

171.2 ± 52.5 ^a

139.6 ± 38.8 ^c

Luminex Abnormal Aβ42 (< 192 pg/ml), n(%)

n.a.

n.a.

n.a.

156 (42%)

403 (64.8%) ^a

210 (92.1%) ^c

Elecsys T-tau (pg/ml), mean ± SD

n.a.

n.a.

n.a.

238.5 ± 90

284.9 ± 126.7 ^a

370.2 ± 144.4 ^c

Elecsys P-tau (pg/ml), mean ± SD

n.a.

n.a.

n.a.

21.9 ± 9.2

27.6 ± 14.4 ^a

36.9 ± 15.7 ^c

Elecsys Aβ42 (pg/ml), mean ± SD

n.a.

n.a.

n.a.

1337 ± 647.9

1020.7 ± 554.8 ^a

694.6 ± 420.7 ^c

Elecsys Abnormal Aβ42 (< 880 pg/ml), n (%)

n.a.

n.a.

n.a.

104 (28%)

325 (53%) ^a

189 (85%) ^c